Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
MSCL.TO Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Satellos Bioscience Inc.TSX: MSCL.TO
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit remains negative
Q1 FY2026 gross profit was -$983, compared with -$1.01K a year earlier. Trailing-twelve-month gross profit was -$5.77K.
Context
- Gross profit grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$983 or moves back toward the trailing-twelve-month quarterly average of -$1.44K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
Mixed currencies · from the income statement
- Latest · FY2025
- (5.09K) USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.09K) | — |
| FY2024 | 2024-12-31 | (20K) | +99.8% |
| FY2023 | 2023-12-31 | (8.82M) | -136.1% |
| FY2022 | 2022-12-31 | (3.73M) | -2153.7% |
| FY2021 | 2021-12-31 | (165.69K) | — |
Gross Profit vs competitors
How MSCL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | -CA$5K CAD | +37.5% | — | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | -$5.77K USD | — | — | — |
| LTM Mar 2026 | -CA$103.71K CAD | +23.4% | — | — | |
| LTM Apr 2026 | -CA$256.13K CAD | +40.2% | — | — | |
| Peer median (excluding MSCL.TO) | — | +37.5% | — | — | |
Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 165.69K | 3.73M | 8.82M | 20K | 5.09K |
| Gross Profit | (165.69K) | (3.73M) | (8.82M) | (20K) | (5.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.88M | 2.59M | 8.82M | 19.6M | 18.75M |
| Selling, General & Admin | 2.8M | 5.49M | 6.64M | 8.19M | 7.44M |
| Operating Expenses | 4.7M | 4.69M | 15.46M | 27.79M | 26.92M |
| Depreciation & Amortization | 165.69K | 337K | 7K | 20K | 5.09K |
| EBITDA | (4.6M) | (8.09M) | (15.71M) | (28.08M) | (26.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (6.65M) | (8.43M) | (15.46M) | (27.81M) | (26.92M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 7.99K | 63K | 1.33M | 1.37M | 1.38M |
| Interest Expense | 985.33K | 0 | 177K | 0 | 0 |
| Other Income / Expenses | (8.86M) | (2.89M) | (426K) | (291K) | 1.79M |
| Income Before Tax | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.13M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (42.41K) | 5K | 0 | 0 | 175.01K |
| Net Income | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.73) | (3.81) | (2.21) | (2.94) | (1.73) |
| EPS (Diluted) | (7.73) | (3.81) | (2.21) | (2.94) | (1.73) |
| Weighted Avg Shares | 2.01M | 2.97M | 7.2M | 9.56M | 14.6M |
| Weighted Avg Shares (Diluted) | 2.01M | 2.97M | 7.2M | 9.56M | 14.6M |
Satellos Bioscience Inc.
TSX:MSCL.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.